Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m(2)) and dexamethasone (once-weekly Kd70 mg/m(2)) improved progression-free survival compared with twice-weekly carfilzomib (27 mg/m(2)) and dexamethasone (twice-weekly Kd27 mg/m(2)) in patients with relaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., Niesvizky, Ruben, Weisel, Katja, Siegel, David S., Hajek, Roman, Mateos, María-Victoria, Cavo, Michele, Huang, Mei, Zahlten-Kumeli, Anita, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062899/
https://www.ncbi.nlm.nih.gov/pubmed/32152297
http://dx.doi.org/10.1038/s41408-020-0300-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062899/
https://www.ncbi.nlm.nih.gov/pubmed/32152297
http://dx.doi.org/10.1038/s41408-020-0300-y

Ejemplares similares